JP4786538B2 - 親油性薬物送達ビヒクルおよびその使用方法 - Google Patents

親油性薬物送達ビヒクルおよびその使用方法 Download PDF

Info

Publication number: JP4786538B2
Authority: JP; Japan
Prior art keywords: particles; lipid; composition; amb; apolipoprotein
Prior art date: 2003-10-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

JP2006533840A

Other languages

English (en)

Japanese (ja)

Other versions

JP2007526907A (ja

Inventor

ロバートオー．リヤン，

マイケルエヌ．オダ，

Original Assignee

チルドレンズホスピタルアンドリサーチセンターアットオークランド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-01

Filing date

2004-08-06

Publication date

2011-10-05

2004-02-13 Priority claimed from PCT/US2004/004295 external-priority patent/WO2004073684A2/fr

2004-08-06 Application filed by チルドレンズホスピタルアンドリサーチセンターアットオークランド filed Critical チルドレンズホスピタルアンドリサーチセンターアットオークランド

2007-09-20 Publication of JP2007526907A publication Critical patent/JP2007526907A/ja

2011-10-05 Application granted granted Critical

2011-10-05 Publication of JP4786538B2 publication Critical patent/JP4786538B2/ja

2024-08-06 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims description 74
238000012377 drug delivery Methods 0.000 title 1
239000002245 particle Substances 0.000 claims description 374
239000012867 bioactive agent Substances 0.000 claims description 159
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 149
108090000765 processed proteins & peptides Proteins 0.000 claims description 124
102000004196 processed proteins & peptides Human genes 0.000 claims description 114
229920001184 polypeptide Polymers 0.000 claims description 110
239000000203 mixture Substances 0.000 claims description 105
230000004576 lipid-binding Effects 0.000 claims description 95
102000007592 Apolipoproteins Human genes 0.000 claims description 76
108010071619 Apolipoproteins Proteins 0.000 claims description 76
230000000975 bioactive effect Effects 0.000 claims description 75
239000000232 Lipid Bilayer Substances 0.000 claims description 50
230000002209 hydrophobic effect Effects 0.000 claims description 45
150000003904 phospholipids Chemical class 0.000 claims description 30
239000003937 drug carrier Substances 0.000 claims description 24
CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims description 16
229960003724 dimyristoylphosphatidylcholine Drugs 0.000 claims description 16
229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 claims description 16
BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 claims description 16
230000005661 hydrophobic surface Effects 0.000 claims description 13
229940121375 antifungal agent Drugs 0.000 claims description 12
230000004071 biological effect Effects 0.000 claims description 12
206010017533 Fungal infection Diseases 0.000 claims description 9
208000031888 Mycoses Diseases 0.000 claims description 9
239000003429 antifungal agent Substances 0.000 claims description 8
230000004048 modification Effects 0.000 claims description 8
238000012986 modification Methods 0.000 claims description 8
229960003942 amphotericin b Drugs 0.000 claims description 7
238000013268 sustained release Methods 0.000 claims description 7
239000012730 sustained-release form Substances 0.000 claims description 7
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 6
108010059886 Apolipoprotein A-I Proteins 0.000 claims description 5
102000005666 Apolipoprotein A-I Human genes 0.000 claims description 5
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 4
238000001990 intravenous administration Methods 0.000 claims description 4
239000000443 aerosol Substances 0.000 claims description 3
238000007918 intramuscular administration Methods 0.000 claims description 3
238000007912 intraperitoneal administration Methods 0.000 claims description 3
238000007913 intrathecal administration Methods 0.000 claims description 3
238000007911 parenteral administration Methods 0.000 claims description 3
238000010382 chemical cross-linking Methods 0.000 claims description 2
239000003431 cross linking reagent Substances 0.000 claims description 2
229940098178 ambisome Drugs 0.000 description 145
150000002632 lipids Chemical class 0.000 description 87
210000004027 cell Anatomy 0.000 description 45
238000009472 formulation Methods 0.000 description 40
241000699670 Mus sp. Species 0.000 description 38
108090000623 proteins and genes Proteins 0.000 description 28
102000004169 proteins and genes Human genes 0.000 description 26
229940127093 camptothecin Drugs 0.000 description 25
KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 24
VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical group C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 24
VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 24
235000018102 proteins Nutrition 0.000 description 24
230000008685 targeting Effects 0.000 description 23
238000011282 treatment Methods 0.000 description 23
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
230000000694 effects Effects 0.000 description 16
238000002360 preparation method Methods 0.000 description 16
230000002538 fungal effect Effects 0.000 description 15
239000000243 solution Substances 0.000 description 15
230000000843 anti-fungal effect Effects 0.000 description 14
-1 natural variants Proteins 0.000 description 14
239000008194 pharmaceutical composition Substances 0.000 description 14
238000010348 incorporation Methods 0.000 description 13
108020004414 DNA Proteins 0.000 description 12
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
239000012736 aqueous medium Substances 0.000 description 12
230000027455 binding Effects 0.000 description 12
108020001507 fusion proteins Proteins 0.000 description 12
102000037865 fusion proteins Human genes 0.000 description 12
239000002904 solvent Substances 0.000 description 12
239000000126 substance Substances 0.000 description 12
230000012010 growth Effects 0.000 description 11
230000008569 process Effects 0.000 description 11
150000001413 amino acids Chemical group 0.000 description 10
239000000872 buffer Substances 0.000 description 10
239000003795 chemical substances by application Substances 0.000 description 10
RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 10
229960004884 fluconazole Drugs 0.000 description 10
230000003993 interaction Effects 0.000 description 10
238000000527 sonication Methods 0.000 description 10
239000006185 dispersion Substances 0.000 description 9
239000013604 expression vector Substances 0.000 description 9
239000000499 gel Substances 0.000 description 9
239000000725 suspension Substances 0.000 description 9
210000001519 tissue Anatomy 0.000 description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
235000001014 amino acid Nutrition 0.000 description 8
229940024606 amino acid Drugs 0.000 description 8
239000003153 chemical reaction reagent Substances 0.000 description 8
208000015181 infectious disease Diseases 0.000 description 8
VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 8
239000002502 liposome Substances 0.000 description 8
102000005962 receptors Human genes 0.000 description 8
108020003175 receptors Proteins 0.000 description 8
231100000419 toxicity Toxicity 0.000 description 8
230000001988 toxicity Effects 0.000 description 8
102100034184 Macrophage scavenger receptor types I and II Human genes 0.000 description 7
101710134306 Macrophage scavenger receptor types I and II Proteins 0.000 description 7
108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 7
102400000015 Vasoactive intestinal peptide Human genes 0.000 description 7
239000002246 antineoplastic agent Substances 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
235000014113 dietary fatty acids Nutrition 0.000 description 7
239000003814 drug Substances 0.000 description 7
239000000194 fatty acid Substances 0.000 description 7
229930195729 fatty acid Natural products 0.000 description 7
230000014509 gene expression Effects 0.000 description 7
238000001727 in vivo Methods 0.000 description 7
239000000463 material Substances 0.000 description 7
239000002609 medium Substances 0.000 description 7
108020004707 nucleic acids Proteins 0.000 description 7
102000039446 nucleic acids Human genes 0.000 description 7
150000007523 nucleic acids Chemical class 0.000 description 7
239000004094 surface-active agent Substances 0.000 description 7
241000588724 Escherichia coli Species 0.000 description 6
206010028980 Neoplasm Diseases 0.000 description 6
239000013011 aqueous formulation Substances 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
230000037396 body weight Effects 0.000 description 6
210000004899 c-terminal region Anatomy 0.000 description 6
230000008859 change Effects 0.000 description 6
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
239000000470 constituent Substances 0.000 description 6
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
230000034994 death Effects 0.000 description 6
238000000502 dialysis Methods 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
125000000524 functional group Chemical group 0.000 description 6
238000001502 gel electrophoresis Methods 0.000 description 6
238000011534 incubation Methods 0.000 description 6
210000003734 kidney Anatomy 0.000 description 6
239000007788 liquid Substances 0.000 description 6
239000008363 phosphate buffer Substances 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
102000006991 Apolipoprotein B-100 Human genes 0.000 description 5
108010008150 Apolipoprotein B-100 Proteins 0.000 description 5
206010006187 Breast cancer Diseases 0.000 description 5
208000026310 Breast neoplasm Diseases 0.000 description 5
229920000858 Cyclodextrin Polymers 0.000 description 5
101000733802 Homo sapiens Apolipoprotein A-I Proteins 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
210000004556 brain Anatomy 0.000 description 5
238000005119 centrifugation Methods 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
238000002298 density-gradient ultracentrifugation Methods 0.000 description 5
229940079593 drug Drugs 0.000 description 5
238000007710 freezing Methods 0.000 description 5
230000008014 freezing Effects 0.000 description 5
239000011544 gradient gel Substances 0.000 description 5
210000002540 macrophage Anatomy 0.000 description 5
238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 5
239000012071 phase Substances 0.000 description 5
239000007787 solid Substances 0.000 description 5
238000003860 storage Methods 0.000 description 5
230000004083 survival effect Effects 0.000 description 5
231100000440 toxicity profile Toxicity 0.000 description 5
239000013598 vector Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
230000004580 weight loss Effects 0.000 description 5
108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
241000894006 Bacteria Species 0.000 description 4
241000222122 Candida albicans Species 0.000 description 4
102000053602 DNA Human genes 0.000 description 4
241000222722 Leishmania <genus> Species 0.000 description 4
240000004808 Saccharomyces cerevisiae Species 0.000 description 4
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
241000700605 Viruses Species 0.000 description 4
230000000844 anti-bacterial effect Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000004202 carbamide Substances 0.000 description 4
238000012512 characterization method Methods 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
238000001493 electron microscopy Methods 0.000 description 4
235000013305 food Nutrition 0.000 description 4
238000004108 freeze drying Methods 0.000 description 4
230000006870 function Effects 0.000 description 4
244000053095 fungal pathogen Species 0.000 description 4
230000009036 growth inhibition Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
239000003446 ligand Substances 0.000 description 4
230000007774 longterm Effects 0.000 description 4
239000011159 matrix material Substances 0.000 description 4
239000000693 micelle Substances 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 4
239000001965 potato dextrose agar Substances 0.000 description 4
238000003259 recombinant expression Methods 0.000 description 4
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 4
239000001488 sodium phosphate Substances 0.000 description 4
229910000162 sodium phosphate Inorganic materials 0.000 description 4
230000003595 spectral effect Effects 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 4
238000003260 vortexing Methods 0.000 description 4
BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 3
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
102100029470 Apolipoprotein E Human genes 0.000 description 3
101710095339 Apolipoprotein E Proteins 0.000 description 3
208000035143 Bacterial infection Diseases 0.000 description 3
102000000844 Cell Surface Receptors Human genes 0.000 description 3
108010001857 Cell Surface Receptors Proteins 0.000 description 3
108091026890 Coding region Proteins 0.000 description 3
241000221204 Cryptococcus neoformans Species 0.000 description 3
241000450599 DNA viruses Species 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
102400000777 His3-(20-43)-peptide Human genes 0.000 description 3
101000898505 Homo sapiens Histatin-3 Proteins 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
102000001708 Protein Isoforms Human genes 0.000 description 3
108010029485 Protein Isoforms Proteins 0.000 description 3
241000251539 Vertebrata <Metazoa> Species 0.000 description 3
230000005856 abnormality Effects 0.000 description 3
230000003321 amplification Effects 0.000 description 3
238000000149 argon plasma sintering Methods 0.000 description 3
210000001106 artificial yeast chromosome Anatomy 0.000 description 3
208000022362 bacterial infectious disease Diseases 0.000 description 3
235000013361 beverage Nutrition 0.000 description 3
229940095731 candida albicans Drugs 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
235000012000 cholesterol Nutrition 0.000 description 3
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 3
210000003477 cochlea Anatomy 0.000 description 3
230000001268 conjugating effect Effects 0.000 description 3
229940109239 creatinine Drugs 0.000 description 3
229940127089 cytotoxic agent Drugs 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
238000009826 distribution Methods 0.000 description 3
238000000635 electron micrograph Methods 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
239000012634 fragment Substances 0.000 description 3
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 3
239000011521 glass Substances 0.000 description 3
KSXBMTJGDUPBBN-VPKNIDFUSA-N histatin 5 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(O)=O)C1=CN=CN1 KSXBMTJGDUPBBN-VPKNIDFUSA-N 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
239000002054 inoculum Substances 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
238000003199 nucleic acid amplification method Methods 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
238000004806 packaging method and process Methods 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
239000013612 plasmid Substances 0.000 description 3
239000004033 plastic Substances 0.000 description 3
229920003023 plastic Polymers 0.000 description 3
238000003752 polymerase chain reaction Methods 0.000 description 3
108091033319 polynucleotide Proteins 0.000 description 3
102000040430 polynucleotide Human genes 0.000 description 3
239000002157 polynucleotide Substances 0.000 description 3
239000011148 porous material Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000010076 replication Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 3
238000005063 solubilization Methods 0.000 description 3
230000007928 solubilization Effects 0.000 description 3
125000006850 spacer group Chemical group 0.000 description 3
241000894007 species Species 0.000 description 3
238000001228 spectrum Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
238000001890 transfection Methods 0.000 description 3
230000009466 transformation Effects 0.000 description 3
230000007704 transition Effects 0.000 description 3
241001430294 unidentified retrovirus Species 0.000 description 3
BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 2
BVPJPRYNQHAOPQ-UHFFFAOYSA-N 4-nitronaphthalen-1-amine Chemical compound C1=CC=C2C(N)=CC=C([N+]([O-])=O)C2=C1 BVPJPRYNQHAOPQ-UHFFFAOYSA-N 0.000 description 2
102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
108010082126 Alanine transaminase Proteins 0.000 description 2
102100037320 Apolipoprotein A-IV Human genes 0.000 description 2
102100040197 Apolipoprotein A-V Human genes 0.000 description 2
108010061118 Apolipoprotein A-V Proteins 0.000 description 2
108010076807 Apolipoprotein C-I Proteins 0.000 description 2
102000011772 Apolipoprotein C-I Human genes 0.000 description 2
108010024284 Apolipoprotein C-II Proteins 0.000 description 2
102100039998 Apolipoprotein C-II Human genes 0.000 description 2
108010056301 Apolipoprotein C-III Proteins 0.000 description 2
102000030169 Apolipoprotein C-III Human genes 0.000 description 2
102000009333 Apolipoprotein D Human genes 0.000 description 2
108010025614 Apolipoproteins D Proteins 0.000 description 2
241001225321 Aspergillus fumigatus Species 0.000 description 2
241000271566 Aves Species 0.000 description 2
102100030802 Beta-2-glycoprotein 1 Human genes 0.000 description 2
239000004380 Cholic acid Substances 0.000 description 2
108090000197 Clusterin Proteins 0.000 description 2
102000003780 Clusterin Human genes 0.000 description 2
201000007336 Cryptococcosis Diseases 0.000 description 2
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
108010036949 Cyclosporine Proteins 0.000 description 2
241000702421 Dependoparvovirus Species 0.000 description 2
KLFKZIQAIPDJCW-HTIIIDOHSA-N Dipalmitoylphosphatidylserine Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC KLFKZIQAIPDJCW-HTIIIDOHSA-N 0.000 description 2
102000002322 Egg Proteins Human genes 0.000 description 2
108010000912 Egg Proteins Proteins 0.000 description 2
229930186217 Glycolipid Natural products 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
102000000853 LDL receptors Human genes 0.000 description 2
108010001831 LDL receptors Proteins 0.000 description 2
108010063045 Lactoferrin Proteins 0.000 description 2
102000010445 Lactoferrin Human genes 0.000 description 2
WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
108010038049 Mating Factor Proteins 0.000 description 2
FVJZSBGHRPJMMA-IOLBBIBUSA-N PG(18:0/18:0) Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-IOLBBIBUSA-N 0.000 description 2
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
238000000862 absorption spectrum Methods 0.000 description 2
230000009471 action Effects 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
238000013019 agitation Methods 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
108010073614 apolipoprotein A-IV Proteins 0.000 description 2
239000003125 aqueous solvent Substances 0.000 description 2
210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
108010023562 beta 2-Glycoprotein I Proteins 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
125000002091 cationic group Chemical group 0.000 description 2
229960002471 cholic acid Drugs 0.000 description 2
235000019416 cholic acid Nutrition 0.000 description 2
229960001265 ciclosporin Drugs 0.000 description 2
238000010367 cloning Methods 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
229930182912 cyclosporin Natural products 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000002950 deficient Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
235000015872 dietary supplement Nutrition 0.000 description 2
ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 2
235000013345 egg yolk Nutrition 0.000 description 2
210000002969 egg yolk Anatomy 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
230000003203 everyday effect Effects 0.000 description 2
238000002189 fluorescence spectrum Methods 0.000 description 2
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
238000002695 general anesthesia Methods 0.000 description 2
210000003128 head Anatomy 0.000 description 2
239000004009 herbicide Substances 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
230000005660 hydrophilic surface Effects 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
239000002917 insecticide Substances 0.000 description 2
CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 2
229940078795 lactoferrin Drugs 0.000 description 2
235000021242 lactoferrin Nutrition 0.000 description 2
238000007834 ligase chain reaction Methods 0.000 description 2
230000004807 localization Effects 0.000 description 2
230000033001 locomotion Effects 0.000 description 2
229940118019 malondialdehyde Drugs 0.000 description 2
239000012528 membrane Substances 0.000 description 2
PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 2
229960003775 miltefosine Drugs 0.000 description 2
230000035772 mutation Effects 0.000 description 2
230000017066 negative regulation of growth Effects 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
239000013600 plasmid vector Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
239000000047 product Substances 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
238000003756 stirring Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000010257 thawing Methods 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 description 1
PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
HKJKONMZMPUGHJ-UHFFFAOYSA-N 4-amino-5-hydroxy-3-[(4-nitrophenyl)diazenyl]-6-phenyldiazenylnaphthalene-2,7-disulfonic acid Chemical compound OS(=O)(=O)C1=CC2=CC(S(O)(=O)=O)=C(N=NC=3C=CC=CC=3)C(O)=C2C(N)=C1N=NC1=CC=C([N+]([O-])=O)C=C1 HKJKONMZMPUGHJ-UHFFFAOYSA-N 0.000 description 1
OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
206010000117 Abnormal behaviour Diseases 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
101710120040 Antifungal peptide Proteins 0.000 description 1
108700042778 Antimicrobial Peptides Proteins 0.000 description 1
102000044503 Antimicrobial Peptides Human genes 0.000 description 1
102000008128 Apolipoprotein E3 Human genes 0.000 description 1
108010060215 Apolipoprotein E3 Proteins 0.000 description 1
241000255789 Bombyx mori Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
101800001415 Bri23 peptide Proteins 0.000 description 1
102400000107 C-terminal peptide Human genes 0.000 description 1
101800000655 C-terminal peptide Proteins 0.000 description 1
YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
241000251204 Chimaeridae Species 0.000 description 1
LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
108010073254 Colicins Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
241000938605 Crocodylia Species 0.000 description 1
241001337994 Cryptococcus <scale insect> Species 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
108010002069 Defensins Proteins 0.000 description 1
102000000541 Defensins Human genes 0.000 description 1
ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
208000000059 Dyspnea Diseases 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
108010049047 Echinocandins Proteins 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
206010015548 Euthanasia Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
241000233866 Fungi Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
206010018910 Haemolysis Diseases 0.000 description 1
101000771674 Homo sapiens Apolipoprotein E Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
241001496375 Iris albicans Species 0.000 description 1
102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
241000222727 Leishmania donovani Species 0.000 description 1
241000222732 Leishmania major Species 0.000 description 1
208000004554 Leishmaniasis Diseases 0.000 description 1
241000270322 Lepidosauria Species 0.000 description 1
206010067125 Liver injury Diseases 0.000 description 1
108060003100 Magainin Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
108010036176 Melitten Proteins 0.000 description 1
241000600389 Myiotheretes fumigatus Species 0.000 description 1
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
206010029155 Nephropathy toxic Diseases 0.000 description 1
102000003797 Neuropeptides Human genes 0.000 description 1
108090000189 Neuropeptides Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
206010053159 Organ failure Diseases 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
241001494479 Pecora Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
241000282887 Suidae Species 0.000 description 1
229940123237 Taxane Drugs 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
102000012088 Vasoactive Intestinal Peptide Receptors Human genes 0.000 description 1
108010075974 Vasoactive Intestinal Peptide Receptors Proteins 0.000 description 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 description 1
SWPYNTWPIAZGLT-UHFFFAOYSA-N [amino(ethoxy)phosphanyl]oxyethane Chemical compound CCOP(N)OCC SWPYNTWPIAZGLT-UHFFFAOYSA-N 0.000 description 1
208000028752 abnormal posture Diseases 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
108700025316 aldesleukin Proteins 0.000 description 1
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
229940087168 alpha tocopherol Drugs 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
229940035674 anesthetics Drugs 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
ZDINGUUTWDGGFF-UHFFFAOYSA-N antimony(5+) Chemical compound [Sb+5] ZDINGUUTWDGGFF-UHFFFAOYSA-N 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229940091771 aspergillus fumigatus Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
230000003385 bacteriostatic effect Effects 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
238000007707 calorimetry Methods 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
210000002230 centromere Anatomy 0.000 description 1
229940106189 ceramide Drugs 0.000 description 1
ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
229930183167 cerebroside Natural products 0.000 description 1
150000001784 cerebrosides Chemical class 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
229940099352 cholate Drugs 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000009668 clonal growth Effects 0.000 description 1
238000009643 clonogenic assay Methods 0.000 description 1
231100000096 clonogenic assay Toxicity 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000011443 conventional therapy Methods 0.000 description 1
229960004544 cortisone Drugs 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
230000002354 daily effect Effects 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
150000001982 diacylglycerols Chemical class 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
229960003529 diazepam Drugs 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
150000002019 disulfides Chemical class 0.000 description 1
229960003668 docetaxel Drugs 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000011363 dried mixture Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
241001493065 dsRNA viruses Species 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000008393 encapsulating agent Substances 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
NSYZCCDSJNWWJL-YXOIYICCSA-N erythromycin ethylsuccinate Chemical compound O1[C@H](C)C[C@H](N(C)C)[C@@H](OC(=O)CCC(=O)OCC)[C@@H]1O[C@H]1[C@@](O)(C)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(OC)C2)[C@@H]1C NSYZCCDSJNWWJL-YXOIYICCSA-N 0.000 description 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
ISVXIZFUEUVXPG-UHFFFAOYSA-N etiopurpurin Chemical compound CC1C2(CC)C(C(=O)OCC)=CC(C3=NC(C(=C3C)CC)=C3)=C2N=C1C=C(N1)C(CC)=C(C)C1=CC1=C(CC)C(C)=C3N1 ISVXIZFUEUVXPG-UHFFFAOYSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
230000005284 excitation Effects 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000011888 foil Substances 0.000 description 1
229960000304 folic acid Drugs 0.000 description 1
235000019152 folic acid Nutrition 0.000 description 1
239000011724 folic acid Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
230000001408 fungistatic effect Effects 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
150000002270 gangliosides Chemical class 0.000 description 1
239000007789 gas Substances 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
239000003193 general anesthetic agent Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
229960002867 griseofulvin Drugs 0.000 description 1
DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
230000007407 health benefit Effects 0.000 description 1
230000008588 hemolysis Effects 0.000 description 1
231100000234 hepatic damage Toxicity 0.000 description 1
231100000304 hepatotoxicity Toxicity 0.000 description 1
108060003558 hepcidin Proteins 0.000 description 1
102000018511 hepcidin Human genes 0.000 description 1
229940066919 hepcidin Drugs 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
102000051062 human APOA1 Human genes 0.000 description 1
102000053020 human ApoE Human genes 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
125000001165 hydrophobic group Chemical group 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
239000003547 immunosorbent Substances 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000013554 lipid monolayer Substances 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
229920006008 lipopolysaccharide Polymers 0.000 description 1
239000004973 liquid crystal related substance Substances 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
230000008818 liver damage Effects 0.000 description 1
230000007056 liver toxicity Effects 0.000 description 1
244000144972 livestock Species 0.000 description 1
238000004020 luminiscence type Methods 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229960004452 methionine Drugs 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
150000002759 monoacylglycerols Chemical class 0.000 description 1
238000004264 monolayer culture Methods 0.000 description 1
231100000417 nephrotoxicity Toxicity 0.000 description 1
230000007694 nephrotoxicity Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
229960000988 nystatin Drugs 0.000 description 1
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
238000003305 oral gavage Methods 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000008520 organization Effects 0.000 description 1
239000005022 packaging material Substances 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000000123 paper Substances 0.000 description 1
238000011192 particle characterization Methods 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
239000000816 peptidomimetic Substances 0.000 description 1
239000000575 pesticide Substances 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
208000001297 phlebitis Diseases 0.000 description 1
150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
150000003905 phosphatidylinositols Chemical class 0.000 description 1
238000002428 photodynamic therapy Methods 0.000 description 1
239000003504 photosensitizing agent Substances 0.000 description 1
235000002378 plant sterols Nutrition 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
229920002627 poly(phosphazenes) Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000003910 polypeptide antibiotic agent Substances 0.000 description 1
229920000379 polypropylene carbonate Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000012545 processing Methods 0.000 description 1
229940087463 proleukin Drugs 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
239000001294 propane Substances 0.000 description 1
229940043274 prophylactic drug Drugs 0.000 description 1
239000012658 prophylactic medication Substances 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
244000000040 protozoan parasite Species 0.000 description 1
238000011084 recovery Methods 0.000 description 1
210000005084 renal tissue Anatomy 0.000 description 1
230000008521 reorganization Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
229930002330 retinoic acid Natural products 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000013341 scale-up Methods 0.000 description 1
238000013391 scatchard analysis Methods 0.000 description 1
102000035013 scavenger receptor class A Human genes 0.000 description 1
108091005451 scavenger receptor class A Proteins 0.000 description 1
102000014452 scavenger receptors Human genes 0.000 description 1
108010078070 scavenger receptors Proteins 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000009919 sequestration Effects 0.000 description 1
KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
235000015500 sitosterol Nutrition 0.000 description 1
229950005143 sitosterol Drugs 0.000 description 1
NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
239000007974 sodium acetate buffer Substances 0.000 description 1
239000011343 solid material Substances 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
150000003408 sphingolipids Chemical class 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
238000000528 statistical test Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
239000012134 supernatant fraction Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
102000055501 telomere Human genes 0.000 description 1
108091035539 telomere Proteins 0.000 description 1
210000003411 telomere Anatomy 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
239000010409 thin film Substances 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
229960000984 tocofersolan Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
239000012581 transferrin Substances 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
238000002371 ultraviolet--visible spectrum Methods 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
238000012800 visualization Methods 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
239000011719 vitamin A Substances 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
229940045997 vitamin a Drugs 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
239000007222 ypd medium Substances 0.000 description 1
239000002076 α-tocopherol Substances 0.000 description 1
235000004835 α-tocopherol Nutrition 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Dispersion Chemistry (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

JP2006533840A 2003-10-01 2004-08-06 親油性薬物送達ビヒクルおよびその使用方法 Expired - Fee Related JP4786538B2 (ja)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US50803503P	2003-10-01	2003-10-01
US60/508,035		2003-10-01
USPCT/US04/004295		2004-02-13
PCT/US2004/004295 WO2004073684A2 (fr)	2003-02-14	2004-02-13	Vehicule d'administration de medicament lipophile et methodes d'utilisation correspondantes
USPCT/US2004/004295		2004-02-13
PCT/US2004/025412 WO2005039534A1 (fr)	2003-10-01	2004-08-06	Vehicule d'administration de medicament lipophile et methodes d'utilisation de ce vehicule

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2010173171A Division JP2010248255A (ja)	2003-10-01	2010-07-30	親油性薬物送達ビヒクルおよびその使用方法

Publications (2)

Publication Number	Publication Date
JP2007526907A JP2007526907A (ja)	2007-09-20
JP4786538B2 true JP4786538B2 (ja)	2011-10-05

Family

ID=34910664

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP2006533840A Expired - Fee Related JP4786538B2 (ja)	2003-10-01	2004-08-06	親油性薬物送達ビヒクルおよびその使用方法
JP2010173171A Withdrawn JP2010248255A (ja)	2003-10-01	2010-07-30	親油性薬物送達ビヒクルおよびその使用方法

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2010173171A Withdrawn JP2010248255A (ja)	2003-10-01	2010-07-30	親油性薬物送達ビヒクルおよびその使用方法

Country Status (5)

Country	Link
EP (1)	EP1677763A1 (fr)
JP (2)	JP4786538B2 (fr)
AU (1)	AU2004283078A1 (fr)
CA (1)	CA2541117A1 (fr)
WO (1)	WO2005039534A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2314285B2 (fr)	2003-02-14	2019-09-18	Children's Hospital & Research Center at Oakland	Véhicule pour l'administration de médicaments lipophiliques et les méthodes pour son utilisation
GB0329958D0 (en)	2003-12-24	2004-01-28	Univ Manchester	Treatment of viral infections
GB0404374D0 (en)	2004-02-27	2004-03-31	Univ Manchester	Treatment of bacterial infections
GB0513096D0 (en)	2005-06-28	2005-08-03	Strathclyde	Treatment of microbial infections
US20090123967A1 (en) *	2005-08-29	2009-05-14	Thomas Scheibel	Modified spider silk proteins
WO2009158678A1 (fr) *	2008-06-27	2009-12-30	Children's Hospital & Research Center At Oakland	Véhicule d'administration d'acide nucléique lipophile et ses procédés d'utilisation
WO2010009277A2 (fr) *	2008-07-15	2010-01-21	Novartis Ag	Compositions de peptides amphipatiques immunogènes
US8734853B2 (en)	2008-11-17	2014-05-27	University Of North Texas Health Science Center At Fort Worth	HDL particles for delivery of nucleic acids
WO2013033513A1 (fr) *	2011-08-31	2013-03-07	University Of Georgia Research Foundation, Inc.	Nanoparticules ciblant l'apoptose
EP2745834B1 (fr)	2012-12-18	2016-09-28	Jens Frauenfeld	Particules de Salipro
LT3043814T (lt)	2013-09-13	2021-02-25	Salipro Biotech AB	Antigenas ir jo gamybos būdas
WO2015138992A1 (fr)	2014-03-14	2015-09-17	University Of Georgia Research Foundation, Inc.	Administration de 3-bromopyruvate dans les mitochondries
US20160346221A1 (en)	2015-06-01	2016-12-01	Autotelic Llc	Phospholipid-coated therapeutic agent nanoparticles and related methods
WO2017120586A1 (fr) *	2016-01-07	2017-07-13	Western University Of Health Sciences	Formulations pour le traitement du cancer de la vessie
US11180535B1 (en)	2016-12-07	2021-11-23	David Gordon Bermudes	Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2609399A1 (fr) *	1987-01-13	1988-07-15	Ire Celltarg Sa	Procede d'incorporation d'un ou plusieurs principes actifs lipophiles dans des lipoproteines, lipoproteines obtenues et composition pharmaceutique les contenant
US5840707A (en) *	1993-10-04	1998-11-24	Albany Medical College	Stabilizing and delivery means of biological molecules
DE19640092A1 (de) *	1996-09-28	1998-04-16	Beiersdorf Ag	Strukturen mit Lipid-Doppelmembranen, in deren lipophilen Bereich längerkettige Moleküle eintauchen oder durch hydrophobe Wechselwirkungen an solche Moleküle angedockt sind
US6514523B1 (en) *	2000-02-14	2003-02-04	Ottawa Heart Institute Research Corporation	Carrier particles for drug delivery and process for preparation
CN101284136A (zh) *	2002-12-03	2008-10-15	布朗歇特洛克菲勒神经科学研究所	传输物质穿过血脑屏障的人工低密度脂蛋白载体
EP2314285B2 (fr) *	2003-02-14	2019-09-18	Children's Hospital & Research Center at Oakland	Véhicule pour l'administration de médicaments lipophiliques et les méthodes pour son utilisation

2004
- 2004-08-06 EP EP04780277A patent/EP1677763A1/fr not_active Withdrawn
- 2004-08-06 CA CA002541117A patent/CA2541117A1/fr not_active Abandoned
- 2004-08-06 JP JP2006533840A patent/JP4786538B2/ja not_active Expired - Fee Related
- 2004-08-06 WO PCT/US2004/025412 patent/WO2005039534A1/fr not_active Ceased
- 2004-08-06 AU AU2004283078A patent/AU2004283078A1/en not_active Abandoned
2010
- 2010-07-30 JP JP2010173171A patent/JP2010248255A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
WO2005039534A8 (fr)	2005-09-09
EP1677763A1 (fr)	2006-07-12
WO2005039534A1 (fr)	2005-05-06
JP2007526907A (ja)	2007-09-20
AU2004283078A1 (en)	2005-05-06
CA2541117A1 (fr)	2005-05-06
JP2010248255A (ja)	2010-11-04

Legal Events

Date	Code	Title	Description
2010-05-06	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100430
2010-07-31	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100730
2010-08-18	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100729
2010-08-27	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100826
2010-11-26	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101125
2010-12-15	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20101125
2011-06-27	TRDD	Decision of grant or rejection written
2011-06-30	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110629
2011-07-07	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01
2011-07-21	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110713
2011-07-22	R150	Certificate of patent or registration of utility model	Free format text: JAPANESE INTERMEDIATE CODE: R150
2011-07-25	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20140722 Year of fee payment: 3
2014-07-08	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2015-07-07	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2016-07-05	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2017-07-04	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2018-07-22	LAPS	Cancellation because of no payment of annual fees

Publication	Publication Date	Title
JP4777873B2 (ja)	2011-09-21	親油性薬物送達ビヒクルおよびこれらの使用方法
JP2010248255A (ja)	2010-11-04	親油性薬物送達ビヒクルおよびその使用方法
JP2010248255A6 (ja)	2011-02-17	親油性薬物送達ビヒクルおよびその使用方法
US11998587B2 (en)	2024-06-04	Lipoprotein complexes and manufacturing and uses thereof
JP2006517972A5 (fr)	2007-01-11
Lin et al.	2012	Structural effects and lipid membrane interactions of the pH-responsive GALA peptide with fatty acid acylation
HK1156863A (en)	2012-06-22	Lipophilic drug delivery vehicle and methods of us thereof
NZ613524B2 (en)	2016-02-02	Lipoprotein complexes and manufacturing and uses thereof
HK1198834B (en)	2019-11-15	Lipoprotein complexes and manufacturing and uses therof
HK1192266A (en)	2014-08-15	Lipoprotein complexes and manufacturing and uses thereof
HK1192266B (en)	2019-11-15	Lipoprotein complexes and manufacturing and uses thereof